Stephen L. Hauser

Stephen L. Hauser

Auto-generated profile, based on publicly available information

Stephen L. Hauser

Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SHStephen L. Hauser
Stephen L. Hauser
EWEmmanuelle Waubant
Emmanuelle Waubant
DADouglas L. Arnold
Douglas L. Arnold
TVTimothy Vollmer
Timothy Vollmer
JAJack Antel
Jack Antel
CSCraig H. Smith
Craig H. Smith
There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes. In a phase 2, double-blind, 48-week trial involving 104 patients with relapsing–remitting multiple sclerosis, we assigned 69 patients to receive 1000 mg of intravenous rituximab and 35 patients to receive placebo on days 1 and 15. The primary end point was the total count of gadolinium-enhancing lesions detected on magnetic resonance imaging scans of the brain at weeks 12, 16, 20, and 24. Clinical outcomes included safety, the proportion of patients who had relapses, and the annualized rate of relapse. As compared with patients who received placebo, patients who received rituximab had reduced counts of total gadolinium-enhancing lesions at weeks 12, 16, 20, and 24 (P<0.001) and of total new gadolinium-enhancing lesions over the same period (P<0.001); these results were sustained for 48 weeks (P<0.001). As compared with patients in the placebo group, the proportion of patients in the rituximab group with relapses was significantly reduced at week 24 (14.5% vs. 34.3%, P=0.02) and week 48 (20.3% vs. 40.0%, P=0.04). More patients in the rituximab group than in the placebo group had adverse events within 24 hours after the first infusion, most of which were mild-to-moderate events; after the second infusion, the numbers of events were similar in the two groups. A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long-term safety or to detect uncommon adverse events. The data provide evidence of B-cell involvement in the pathophysiology of relapsing–remitting multiple sclerosis. (ClinicalTrials.gov number, NCT00097188.)

17 July 2020 in The American Journal of Medicine
Verified
Journal Article
Closed access
SHStephen L. Hauser
Stephen L. Hauser
BCBruce A.C. Cree
Bruce A.C. Cree

6 August 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
SHStephen L. Hauser
Stephen L. Hauser
ABAmit Bar-Or
Amit Bar-Or
JCJeffrey A. Cohen
Jeffrey A. Cohen
GCGiancarlo Comi
Giancarlo Comi
JCJorge Correale
Jorge Correale
LKLudwig Kappos
Ludwig Kappos
Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.

4 November 2020 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
GCGiancarlo Comi
Giancarlo Comi
ABAmit Bar‐Or
Amit Bar‐Or
HLHans Lassmann
Hans Lassmann
AUAntonio Uccelli
Antonio Uccelli
HHHans‐Peter Hartung
Hans‐Peter Hartung
EFExpert Panel Of The 27Th Annual Meeting Of The European Charcot Foundation
Expert Panel Of The 27Th Annual Meeting Of The European Charcot Foundation

15 April 2022 in Science
Verified
Journal Article
Open access
JLJing Li
Jing Li
MZMaxim Zaslavsky
Maxim Zaslavsky
YSYapeng Su
Yapeng Su
JGJing Guo
Jing Guo
MSMichael J. Sikora
Michael J. Sikora
MDMark M Davis
Mark M Davis
In this work, we find that CD8 + T cells expressing inhibitory killer cell immunoglobulin-like receptors (KIRs) are the human equivalent of Ly49 + CD8 + regulatory T cells in mice and are increased in the blood and inflamed tissues of patients with a variety of autoimmune diseases. Moreover, these CD8 + T cells efficiently eliminated pathogenic gliadin-specific CD4 + T cells from the leukocytes of celiac disease patients in vitro. We also find elevated levels of KIR + CD8 + T cells, but not CD4 + regulatory T cells, in COVID-19 patients, correlating with disease severity and vasculitis. Selective ablation of Ly49 + CD8 + T cells in virus-infected mice led to autoimmunity after infection. Our results indicate that in both species, these regulatory CD8 + T cells act specifically to suppress pathogenic T cells in autoimmune and infectious diseases.

21 June 2012 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
PGPierre‐Antoine Gourraud
Pierre‐Antoine Gourraud
HHHanne F. Harbo
Hanne F. Harbo
SHStephen L. Hauser
Stephen L. Hauser
SBSergio Baranzini
Sergio Baranzini